Month: October 2024

However, the absence of toxicity should be confirmed in future by nonclinical safety studies

However, the absence of toxicity should be confirmed in future by nonclinical safety studies. In our preliminary study, we estimated the function of adhesion and haemostasis using this recombinant fibrinogen as a fibrin sealant mimic and obtained almost the same results as obtained using plasma fibrinogen (data not shown). and its cross-linking properties. The basic […]

1 Contrast-enhanced computed tomography findings

1 Contrast-enhanced computed tomography findings. to chronic period pulmonary thromboembolism for most patients. However, the effects of DOAC on acute pulmonary thromboembolism (APTE) in patients with antiphospholipid syndrome (APS) remain obscure. The standard treatment for thrombotic APS is initial anticoagulation with unfractionated heparin or a low-molecular-weight heparin followed by warfarin. DOAC may be useful for […]

Ctrl = 0

Ctrl = 0.0135, 5Gy vs. adenocarcinoma tumors, bilaterally established in 129Sv/Ev mice, to mimic high-tumor-burden settings. The RadScopal approach is comprised of high-dose radiation directed at main tumors with low-dose radiation delivered to secondary tumors to improve the outcomes of systemic immunotherapy. Indeed, the triple therapy with RadScopal + anti-TIGIT + anti-PD1 was able to […]

IA made substantial contribution to conception and design, acquisition of data, analysis and interpretation of data

IA made substantial contribution to conception and design, acquisition of data, analysis and interpretation of data. microangiopathy manifestations were inhibited and renal and cardiac function restored, with no need for other invasive treatments. Conclusions Establishing the diagnosis of atypical hemolytic uremic syndrome in patients presenting with thrombotic microangiopathy is challenging since common symptoms are shared […]

Scroll to top